BioCentury
ARTICLE | Clinical News

Summit discontinues DMD program after Phase II miss

June 29, 2018 3:04 PM UTC

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) discontinued development of ezutromid (SMT C1100) after the candidate failed in the Phase II PhaseOut DMD trial to treat Duchenne muscular dystrophy (DMD).

PhaseOut DMD enrolled 40 DMD patients ages 5-10. Ezutromid missed the open-label, U.S. and U.K. trial's primary endpoint of change in MRI leg muscle parameters after 48 weeks of treatment compared with baseline, as well as a secondary endpoint measuring muscle damage via biopsy. Ezutromid is a small molecule utrophin (UTRN) modulator...

BCIQ Company Profiles

Summit Therapeutics Inc.

BCIQ Target Profiles

Utrophin (UTRN)